Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology

被引：0

作者：

Hayashi, Toshinobu ^{[1
]}

Yamamoto, Shun ^{[2
]}

Miyata, Yoshiharu ^{[3
]}

Takeda, Masayuki ^{[4
]}

Abe, Masakazu ^{[5
]}

Wada, Makoto ^{[6
]}

Iino, Keiko ^{[7
]}

Akechi, Tatsuo ^{[8
]}

Imamura, Chiyo K. ^{[9
]}

Okuyama, Ayako ^{[10
]}

Ozawa, Keiko ^{[11
]}

Kim, Yong-Il ^{[12
]}

Sasaki, Hidenori ^{[13
]}

Satomi, Eriko ^{[14
]}

Tanaka, Ryuhei ^{[15
]}

Nakajima, Takako Eguchi ^{[16
]}

Nakamura, Naoki ^{[17
]}

Nishimura, Junichi ^{[18
]}

Noda, Mayumi ^{[19
]}

Hayashi, Kazumi ^{[20
]}

Higashi, Takahiro ^{[21
]}

Boku, Narikazu ^{[22
]}

Matsumoto, Koji ^{[23
]}

Matsumoto, Yoko ^{[24
]}

Okita, Kenji ^{[25
]}

Yamamoto, Nobuyuki ^{[26
]}

Aogi, Kenjiro ^{[27
]}

Iihara, Hirotoshi ^{[28
]}

机构：

[1] Fukuoka Univ, Fac Pharmaceut Sci, Dept Emergency & Disaster Med Pharm, 8-19-1,Nanakuma,Jonan Ku, Fukuoka, Japan

[2] Natl Canc Ctr, Dept Head & Neck, Esophageal Med Oncol, Tokyo, Japan

[3] Kobe Univ, Dept Artificial Intelligence & Digital Hlth Sci, Grad Sch Med, 7-1-48 Minatojimaminamimachi,Chuo Ku, Kobe, Japan

[4] Nara Med Univ, Dept Epidemiol, 840 Shijo Cho, Kashihara, 6348521, Japan

[5] Hamamatsu Univ Sch Med, Dept Surg, 1-20-1 Handayama,Chuo Ku, Hamamatsu, Shizuoka 4313192, Japan

[6] Osaka Int Canc Inst, Dept Hematol, 3-1-69 Chuo Ku, Osaka, Osaka 5418567, Japan

[7] Natl Coll Nursing, Dept Adult Nursing, 1-2-1,Umezono, Kiyose, Tokyo 2048575, Japan

[8] Nagoya City Univ, Grad Sch Med Sci, Dept Psychiat & Cognit Behav Med, 1 Kawasumi,Mizuho Cho,Mizuho Ku, Nagoya 4678601, Japan

[9] Showa Univ, Adv Canc Translat Res Inst, 1-5-8 Hatanodai,Shinagawa Ku, Tokyo 1428555, Japan

[10] St Lukes Int Univ, Grad Sch Nursing Sci, 10-1 Akashi Cho,Chuo ku, Tokyo 1040044, Japan

[11] Natl Canc Ctr, Inst Canc Control, Div Survivorship, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan

[12] Yodogawa Christians Hosp, Div Med Oncol, 1-7-50 Kunijima,Higasiyodogawa Ku, Osaka, Osaka 5330024, Japan

[13] Fukuoka Univ, Div Med Oncol Hematol & Infect Dis, 7-45-1,Nanakuma,Jonan Ku, Fukuoka 8140180, Japan

[14] Natl Canc Ctr, Dept Palliat Med, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan

[15] Saitama Med Univ, Int Med Ctr, Dept Pediat Hematol & Oncol, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan

[16] Kyoto Univ, Grad Sch Med, Grad Sch Med, 54 Kawahara Cho,Shogoin,Sakyo ku, Kyoto 6068507, Japan

[17] St Marianna Univ, Dept Microbiol, 2-16-1,Sugao, Miyamae, Kawasaki 2168511, Japan

[18] Osaka Int Canc Inst, Dept Gastroenterol Surg, 3-1-69, Osaka 5418567, Japan

[19] Nonprofit Org Sasaeau KaiAlpha, 518-7 Kawado Cho,Chuo Ku, Chiba, Chiba 2600802, Japan

[20] Jikei Univ, Sch Med, Sch Med, Tokyo, Japan

[21] Univ Tokyo, Dept Hlth Serv Res, 7-3-1 Hongo,Bunkyo Ku, Tokyo 1130033, Japan

[22] Univ Tokyo, Inst Med Sci Hosp, Dept Oncol & Gen Med, 4-6-1 Shiroganedai,Minato ku, Tokyo 1088639, Japan

[23] Hyogo Canc Ctr, Div Diagnost Radiol, 13-70 Kitaoji Cho, Akashi, Hyogo 6730021, Japan

[24] Nonprofit Org Ehime Canc Support Orange No Kai, 3-8-24 Furukawaminami, Matsuyama, Ehime 7900943, Japan

[25] Otaru Ekisaikai Hosp, Dept Surg, 1-4-1 Inaho, Otaru, Hokkaido 0470032, Japan

[26] Wakayama Med Univ, Internal Med 3, 811-1 Kimiidera, Wakayama, 6418509, Japan

[27] Natl Hosp Org Shikoku Canc Ctr, Dept Breast Oncol, 160 Kou,Minamiumemoto Machi, Matsuyama, Ehime 7910280, Japan

[28] Gifu Univ Hosp, Dept Pharm, 1-1 Yanagido, Gifu 5011194, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 29卷 / 11期

关键词：

Antiemetics; Carboplatin; Chemotherapy-induced nausea and vomiting; Moderately emetogenic chemotherapy; Neurokinin-1 receptor antagonist; Systematic review and meta-analysis; DOUBLE-BLIND; BROAD RANGE; PHASE-II; APREPITANT; PREVENTION; EFFICACY; CANCER; DEXAMETHASONE; FOSAPREPITANT; PALONOSETRON;

D O I：

10.1007/s10147-024-02623-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundChemotherapy-induced nausea and vomiting (CINV) commonly affects patient quality of life and the overall effectiveness of chemotherapy. This study aimed to evaluate whether adding neurokinin-1 receptor antagonists (NK1RAs) to 5-hydroxytryptamine-3 receptor antagonists (5-HT3RAs) and corticosteroids provides clinically meaningful benefits in preventing CINV in patients receiving moderately emetogenic chemotherapy (MEC).MethodsWe conducted a systematic review of PubMed, Cochrane Library, and Ichushi-Web to identify clinical studies evaluating NK1RAs combined with 5-HT3RAs and dexamethasone for managing CINV in MEC. The endpoints were complete response (CR), complete control (CC), total control (TC), adverse events, and costs. The data were analyzed using a random effects model.ResultsFrom 142 articles identified, 15 randomized controlled trials (RCTs), involving 4,405 patients, were included in the meta-analysis. Approximately 60% of the patients received carboplatin (CBDCA)-based chemotherapy. The meta-analysis showed that triplet antiemetic prophylaxis with NK1RA was significantly more effective for achieving CR than doublet prophylaxis in each phase. Regarding CC, the triplet antiemetic prophylaxis was significantly more effective than the doublet in the overall (risk difference [RD]: 0.11, 95% confidence interval [CI]: 0.06-0.17) and delayed (RD: 0.08, 95% CI: 0.02-0.13) phases. For TC, no significant differences were observed in any phase. Adding NK1RA did not cause adverse events.ConclusionsAdding NK1RA to CBDCA-based chemotherapy has shown clinical benefits. However, the clinical benefits of NK1RA-containing regimens for overall MEC have not yet been established and require RCTs that exclusively evaluate MEC regimens other than CBDCA-based chemotherapy.

引用

页码：1616 / 1631

页数：16

共 50 条

[1] Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology
Nakashima, Kazuhisa
Yokomizo, Ayako
Murakami, Michiyasu
Okita, Kenji
Wada, Makoto
Iino, Keiko
Akechi, Tatsuo
Iihara, Hirotoshi
Imamura, Chiyo K.
Okuyama, Ayako
Ozawa, Keiko
Kim, Yong-il
Sasaki, Hidenori
Satomi, Eriko
Takeda, Masayuki
Tanaka, Ryuhei
Nakajima, Takako Eguchi
Nakamura, Naoki
Nishimura, Junichi
Noda, Mayumi
Hayashi, Kazumi
Higashi, Takahiro
Boku, Narikazu
Matsumoto, Koji
Matsumoto, Yoko
Yamamoto, Nobuyuki
Aogi, Kenjiro
Abe, Masakazu
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (12) : 1785 - 1794
[2] Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology
Murakami, Michiyasu
Miyata, Yoshiharu
Nakashima, Kazuhisa
Abe, Masakazu
Nishimura, Junichi
Wada, Makoto
Iino, Keiko
Akechi, Tatsuo
Iihara, Hirotoshi
Imamura, Chiyo K.
Okuyama, Ayako
Ozawa, Keiko
Kim, Yong-il
Sasaki, Hidenori
Satomi, Eriko
Takeda, Masayuki
Tanaka, Ryuhei
Nakamura, Naoki
Noda, Mayumi
Hayashi, Kazumi
Higashi, Takahiro
Boku, Narikazu
Matsumoto, Koji
Matsumoto, Yoko
Okita, Kenji
Yamamoto, Nobuyuki
Aogi, Kenjiro
Nakajima, Takako Eguchi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (01) : 27 - 39
[3] Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis
Kenjiro Aogi
Hideki Takeuchi
Toshiaki Saeki
Keisuke Aiba
Kazuo Tamura
Keiko Iino
Chiyo K. Imamura
Kenji Okita
Yoshikazu Kagami
Ryuhei Tanaka
Kazuhiko Nakagawa
Hirofumi Fujii
Narikazu Boku
Makoto Wada
Tatsuo Akechi
Hirotoshi Iihara
Shoichiro Ohtani
Ayako Okuyama
Keiko Ozawa
Yong-Il Kim
Hidenori Sasaki
Yasuo Shima
Masayuki Takeda
Eijiro Nagasaki
Toshihiko Nishidate
Takahiro Higashi
Kouichi Hirata
International Journal of Clinical Oncology, 2021, 26 : 1 - 17
[4] Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis
Aogi, Kenjiro
Takeuchi, Hideki
Saeki, Toshiaki
Aiba, Keisuke
Tamura, Kazuo
Iino, Keiko
Imamura, Chiyo K.
Okita, Kenji
Kagami, Yoshikazu
Tanaka, Ryuhei
Nakagawa, Kazuhiko
Fujii, Hirofumi
Boku, Narikazu
Wada, Makoto
Akechi, Tatsuo
Iihara, Hirotoshi
Ohtani, Shoichiro
Okuyama, Ayako
Ozawa, Keiko
Kim, Yong-Il
Sasaki, Hidenori
Shima, Yasuo
Takeda, Masayuki
Nagasaki, Eijiro
Nishidate, Toshihiko
Higashi, Takahiro
Hirata, Kouichi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 1 - 17
[5] Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis
Jordan, Karin
Blaettermann, Luisa
Hinke, Axel
Mueller-Tidow, Carsten
Jahn, Franziska
SUPPORTIVE CARE IN CANCER, 2018, 26 (01) : 21 - 32
[6] Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings—a meta-analysis
Karin Jordan
David G. Warr
Axel Hinke
Linda Sun
Paul J. Hesketh
Supportive Care in Cancer, 2016, 24 : 1941 - 1954
[7] Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?—a systematic review and meta-analysis
Karin Jordan
Luisa Blättermann
Axel Hinke
Carsten Müller-Tidow
Franziska Jahn
Supportive Care in Cancer, 2018, 26 : 21 - 32
[8] Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis
Jordan, Karin
Warr, David G.
Hinke, Axel
Sun, Linda
Hesketh, Paul J.
SUPPORTIVE CARE IN CANCER, 2016, 24 (05) : 1941 - 1954
[9] Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology
Yokomizo, Ayako
Nakashima, Kazuhisa
Iba, Arisa
Okita, Kenji
Wada, Makoto
Iino, Keiko
Akechi, Tatsuo
Iihara, Hirotoshi
Imamura, Chiyo K.
Okuyama, Ayako
Ozawa, Keiko
Kim, Yong-Il
Sasaki, Hidenori
Satomi, Eriko
Takeda, Masayuki
Tanaka, Ryuhei
Nakajima, Takako Eguchi
Nakamura, Naoki
Nishimura, Junichi
Noda, Mayumi
Hayashi, Kazumi
Higashi, Takahiro
Boku, Narikazu
Matsumoto, Koji
Matsumoto, Yoko
Yamamoto, Nobuyuki
Aogi, Kenjiro
Abe, Masakazu
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (11) : 1632 - 1640
[10] Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023
Kobayashi, Masamitsu
Kako, Jun
Iba, Arisa
Okuyama, Ayako
Ozawa, Keiko
Abe, Masakazu
Wada, Makoto
Akechi, Tatsuo
Iihara, Hirotoshi
Imamura, Chiyo K.
Kim, Yong-Il
Sasaki, Hidenori
Satomi, Eriko
Takeda, Masayuki
Tanaka, Ryuhei
Nakajima, Takako Eguchi
Nakamura, Naoki
Nishimura, Junichi
Noda, Mayumi
Hayashi, Kazumi
Higashi, Takahiro
Boku, Narikazu
Matsumoto, Koji
Matsumoto, Yoko
Okita, Kenji
Yamamoto, Nobuyuki
Aogi, Kenjiro
Iino, Keiko
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, : 889 - 898

← 1 2 3 4 5 →